# A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

> **NCT02400385** · PHASE2 · WITHDRAWN · sponsor: **California Pacific Medical Center Research Institute**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** sunitinib
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT02400385
- **Lead sponsor:** California Pacific Medical Center Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** With recent advances in immunotherapy scientific question not significant
- **Last updated:** 2017-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400385, "A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02400385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*